ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors
Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
1. An oligonucleotide having the nucleotide sequence as shown in any one of SEQ ID NOS: 56-59, 61-63, 65, or 88 in the SEQUENCE LISTING, or a pharmacologically acceptable salt thereof, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
2. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one sugar constituting the oligonucleotide is modified, the sugar constituting the oligonucleotide is D-ribofuranose, and the modification of the sugar is modification of the hydroxyl group at position 2′ of D-ribofuranose.
3. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 2 , wherein the modification of the sugar is 2′-O-alkylation and/or 2′-O,4′-C-alkylenation of the D-ribofuranose.
4. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one of sugar constituting the oligonucleotide is modified, and said modification is selected from the group consisting of 2′-O-methylation of D-ribofuranose, 2′-O-aminoethylation of D-ribofuranose, 2′-O-propylation of D-ribofuranose, 2′-O-allylation of D-ribofuranose, 2′-O-methoxyethylation of D-ribofuranose, 2′-O-butylation of D-ribofuranose, 2′-O-pentylation of D-ribofuranose, 2′-O-propargylation of D-ribofuranose, 2′-O,4′-C-ethylenation of D-ribofuranose, 2′-O,4′-C-methylenation of D-ribofuranose, 2′-O,4′-C-propylenation of D-ribofuranose, 2′-O,4′-C-tetramethylation of D-ribofuranose, 2′-O,4′-C-pentamethylation of D-ribofuranose, 3′-deoxy-3′-amino-2′-deoxy-D-ribofuranose, and 3′-deoxy-3′-amino-2′-deoxy-2′-fluoro-D-ribofuranose.
5. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one of phosphate constituting the oligonucleotide is modified and the modification of the phosphate is thioation of the phosphate group.
6. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one sugar constituting the oligonucleotide is modified and at least one phosphate constituting the oligonucleotide is modified.
7. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one sugar constituting the oligonucleotide is modified.
8. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein at least one phosphate constituting the oligonucleotide is modified.
9. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide consists of the nucleotide sequence as shown in any one of SEQ ID NOS: 56-59, 61-63, 65, or 88 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
10. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 56 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
11. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 57 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
12. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 58 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
13. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 59 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
14. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 61 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
15. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 62 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
16. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 63 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
17. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 65 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.
18. The oligonucleotide or a pharmacologically acceptable salt thereof according to claim 1 , wherein said oligonucleotide has the nucleotide sequence as shown in SEQ ID NO: 88 in the SEQUENCE LISTING, wherein at least one sugar constituting the oligonucleotide is modified and/or at least one phosphate constituting the oligonucleotide is modified.